A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance Test

Phase 2 Completed 31 enrolled Aphaia Pharma US LLC

RandomizedCrossoverQuadruple-blindTreatment

Summary

The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose \[Aphaia technology, AT\]) in participants with pre-diabetes (pathological Oral Glucose Tolerance Test (OGTT)).

Timeline

Start: 2023-03-31
Primary completion: 2024-02-12
Completion: 2024-02-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	APHD-012	Unknown	12 g	—

A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance Test

Summary

Timeline

Drugs

Indications